Pancreatic insulinomas: Our 15-year surgical experience

Furkan Karahan,Serkan Karaıslı,Arif Atay,Osman Nuri Dilek,Mehmet Hacıyanlı

DOI: https://doi.org/10.1177/00369330241289009

2024-10-17

Scottish Medical Journal

Abstract:Scottish Medical Journal, Ahead of Print. BackgroundInsulinomas are rare endocrine tumors of the pancreas. The majority are benign, sporadic, and solitary. Surgery is the only curative treatment. In this study, we present our experiences with the perioperative management of sporadic and benign pancreatic insulinomas.MethodsPatients who underwent surgery for pancreatic insulinoma in our clinic between 2008 and 2023 were retrospectively reviewed. Demographic data, preferred radiological methods, surgical procedures, and morbidity and mortality data were evaluated. Patients with malignant, invasive, or familial multiple endocrine neoplasia mutations were excluded from the study.ResultsNineteen patients underwent surgery, with a median age of 49 years (range: 33–85). Symptoms related to hypoglycemia were the most commonly observed. The tumor location was identified preoperatively in 74% of cases using computed tomography. Palpation and intraoperative ultrasound identified the tumor location in 88% of patients. Enucleation (53%) were the most common surgical procedures. Pancreatic fistula occurred in three patients (17%). While serious morbidity was lower in patients who underwent enucleation, the rate of fistula formation was higher.ConclusionThe accurate localization of insulinomas plays a crucial role in determining the appropriate surgical procedure. With high success rates and lower morbidity, enucleation is the recommended procedure for suitable patients.

medicine, general & internal